IQIRVO® (elafibranor)
Primary Biliary Cholangitis
ApprovedCommercial
Key Facts
About Ipsen
Ipsen is a well-established French biopharmaceutical company that has evolved from its 1986 founding to become a global leader in specialty care medicines. The company focuses on areas of high unmet medical need across oncology, rare diseases, and neuroscience, with particular expertise in neuroendocrine tumors, rare liver conditions like PBC, and neurological disorders including spasticity. Ipsen's strategy emphasizes targeted innovation and strategic partnerships to accelerate drug development and expand their pipeline. The company has demonstrated strong financial performance with consistent growth and maintains a robust balance sheet to support continued R&D investments and pipeline expansion.
View full company profile